Journals / Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi / 2020 / Cilt: 25 - Sayı: 4

Acinetobacter baumannii Infections and Antibiotic Resistance in Hospitalized Patients in an Education and Research Hospital: A Six-Year Analysis

Bir Eğitim ve Araştırma Hastanesinde Yatan Hastalarda Acinetobacter baumannii İnfeksiyonları ve Antibiyotik Direnci: Altı Yıllık Analiz

Pages
563–571
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There is a clear need for new and effective antimicrobial agents in the treatment of resistant A. baumanii infections.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Acinetobacter baumanii causes difficulties in the treatment of nosocomial infections due to increasing resistance worldwide.
📊
Key Findings & Data:With an increase in resistant infections, the use of colistin has come to the fore.
💡
Conclusion & Impact:There is a clear need for new and effective antimicrobial agents in the treatment of resistant A. baumanii infections.
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Introduction: Acinetobacter baumanii causes difficulties in the treatment of nosocomial infections due to increasing resistance worldwide. With an increase in resistant infections, the use of colistin has come to the fore. We aimed to investigate the antimicrobialresistance profile of A. baumanii strains isolated from clinical specimens as hospital-acquired colonizations and infection agents and to evaluate the clinical and microbiologic responses and adverse effects of antibiotic regimens used in patients who were isolated because of having infectious agents.Materials and Methods: A retrospective descriptive study of 326 adult patients with nosocomial A. baumannii colonizations and infections was conducted between January 2012 and December 2017 in Niğde Education and Research Hospital. In addition, a totalof 212 adult patients who received at least 72 hours of antimicrobial therapy were evaluated. Standard and automated methods were used to identify isolated strains and antibiotic susceptibility. The antimicrobial susceptibility profile change over the 6-year period was evaluated. Adverse effects, and clinical and microbiologic response were evaluated in patients receiving antimicrobial therapy. Analysis of the variables was performed using SPSS 22.0 (IBM Corporation, Armonk, New York, United States).Results: When antimicrobial resistance rates were examined, it was seen that imipenem (99.7%), ampicillin sulbactam (81.6%), cefoperazone sulbactam (60.3%), netilmicin (89.4%), tobramycin (88.4%), gentamicin (83.1%), amikacin (91.6%) and tigecycline (33.7%) had resistance rates; colistin resistance was not detected in the isolates. Resistance rate to other antibiotic groups was 100%. The resistance rates of ampicillin sulbactam, cefoperazone sulbactam, gentamicin, amikacin, and tigecycline were found to be statistically significant (p 0.05).Conclusion: In accordance with the global data, antimicrobial resistance rate in A. baumanii isolates was found to be high in our study. Treatment regimens in which colistin is used with other antimicrobial agents have no superiority in terms of efficacy and adverse effects. There is a clear need for new and effective antimicrobial agents in the treatment of resistant A. baumanii infections.

Özet

Giriş: Acinetobacter baumannii, dünya genelinde artan direnç ile beraber, tedavisi zor nozokomiyal infeksiyonlara neden olmaktadır. Dirençli infeksiyonlardaki artışla birlikte, kolistin kullanımı tekrar ön plana çıkmıştır. Bu çalışma ile, hastane kaynaklı kolonizasyon ve infeksiyon etkeni olarak klinik örneklerden izole edilen A. baumannii suşlarının antimikrobiyal direnç profilini araştırmayı ve infeksiyon etkeni olarak izole edilen hastalarda kullanılan kolistin temelli antibiyotik rejimlerinin klinik ve mikrobiyolojik yanıt ve yan etkilerini değerlendirmeyi amaçladık. Materyal ve Metod: Tanımlayıcı, retrospektif bir çalışma olup, Ocak 2012-Aralık 2017 tarihleri arasında Niğde Eğitim Araştırma Hastanesi’nde yatarak izlenen ve çeşitli kültürlerinde dirençli A. baumannii üremesi olan 326 erişkin hasta ile A. baumannii’ninhastane infeksiyonu etkeni olarak saptandığı ve en az 72 saat antimikrobiyal tedavi almış 212 erişkin hasta çalışmaya dahil edildi. Antimikrobiyal duyarlılık profilinin 6 yıl içindeki yıllara göre değişimi değerlendirildi. İzole edilen suşların tanımlanmasında ve antibiyotik duyarlılıklarının saptanmasında standart ve otomatize yöntemler kullanıldı. Antimikrobiyal tedavi verilen hastalarda yan etkiler, klinik yanıt ve mikrobiyolojik yanıt değerlendirildi. Değişkenlerin analizinde SPSS 22.0 (IBM Corparation, Armonk, New York, United States) programı kullanıldı. Bulgular: Antimikrobiyal direnç oranları incelendiğinde, imipenem %99.7, ampisilin sulbaktam %81.6, sefoperazon sulbaktam%60.3, netilmisin %89.4, tobramisin %88.4, gentamisin %83.1, amikasin %91.6 ve tigesiklin direncinin %33.7 oranında olduğu görülürken, izolatlarda kolistin direnci tespit edilmedi. Diğer antibiyotik gruplarına karşı direnç oranı %100 idi. Altı yıl içinde değişen direnç oranları incelendiğinde, ampisilin sulbaktam, sefoperazon sulbaktam, gentamisin, amikasin ve tigesiklin dirençlerindeki değişikliğin istatistiksel olarak anlamlı olduğu saptandı (p 0.05). Sonuç: Global verilerle uyumlu olarak, çalışmamızda A. baumannii izolatlarında antimikrobiyal direncin yüksek olduğu görülmektedir. Kolistinin diğer antimikrobiyal ajanlarla beraber kullanıldığı tedavi rejimlerinin etkinlik ve yan etki açısından birbirlerine üstünlüğünün bulunmadığı saptanmıştır. Dirençli A. baumannii infeksiyonlarının tedavisinde yeni ve etkili antimikrobiyal ajanlara ihtiyaç olduğu nettir

🔖

Cite This Article

GÜLEN, T. A., KAYABAŞ, Ü., İMRE, A., ÖDEMİŞ, İ. (2022). Acinetobacter baumannii Infections and Antibiotic Resistance in Hospitalized Patients in an Education and Research Hospital: A Six-Year Analysis. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, Cilt: 25 - Sayı: 4, 563–571. https://ajindex.com/articles/517104

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Xie R, Zhang XD, Zhao Q, Peng B, Zheng J. Analysis of global prevalence of antibiotic resistance in Acinetobacter baumannii infections disclosed a faster increase in OECD countries. Emerg Microbes Infect 2018;7(1):31
  2. Gulen TA, Guner R, Celikbilek N, Keske S, Tasyaran M. Clinical importance and cost of bacteremia caused by nosocomial multi drug resistant Acinetobacter baumannii. Int J Infect Dis 2015;38:32-5
  3. Surveillance of antimicrobial resistance in Europe. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2016. Available from: https://ecdc. europa.eu/sites/portal/files/documents/AMR-surveillance-Europe-2016.pdf 4. Manchanda V, Sanchaita S, Singh NP. Multidrug resistant Acinetobacter. J Glob Infect Dis 2010;2(3):291-304
  4. Kalin G, Alp E, Akin A, Coskun R, Doganay M. Comparison of colistin and colistin/sulbactam for thetreatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. Infection 2014;42:37–4
  5. Batirel A, Balkan II, Karabay O, Agalar C, Akalin S, Alici O, et al. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis 2014;33(8):1311-22
  6. Liang CA, Lin YC, Lu PL, Chen HC, Chang HL, Sheu CC. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Clin Microbiol Infect 2018;24(8):908
  7. Horan T, Andrus M, Dudeck M. CDC/NHSN surveillance definition of health care associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309–32
  8. Paul M, Bishara J, Levcovich A, Chowers M, Goldberg E, Singer P, et al. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother 2010;65:1019–27
  9. European Committee on Antimicrobial Susceptibility Testing (EUCAST) 2012. Breakpoint tables for interpretation of MICs and zone diameters. Version 2.0, Accessed date: January 1 2012. Available from: http://www.eucast.org/ clinical_breakpoints/
  10. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Twentieth Informational Supplement. CLSI Document M100-S21. Wayne, PA: CLSI, 2011
  11. Asif M, Alvi IA, Rehman SU. Insight into Acinetobacter baumannii: pathogenesis, global resistance, me